MiR-603 promotes glioma cell growth via Wnt/β-catenin pathway by inhibiting WIF1 and CTNNBIP1

Cancer Letters

Volumn 360, Issue 1, 2015, Pages 76-86

  Guo, Mian ^a   Zhang, Xiaoming ^a   Wang, Guangzhi ^a   Sun, Jiahang ^a   Jiang, Zhenfeng ^c   Khadarian, Kevork ^b   Yu, Shan ^a   Zhao, Yan ^a   Xie, Chuncheng ^c   Zhang, Kelvin ^d   Zhu, Minwei ^c   Shen, Hong ^c   Lin, Zhiguo ^c   Jiang, Chuanlu ^a   Shen, Jia ^b   Zheng, Yongri ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b UCLA SCHOOL OF DENTISTRY   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CTNNBIP1; Glioma; MiR 603; WIF1; Wnt catenin

Indexed keywords

BETA CATENIN; BETA CATENIN INTERACTING PROTEIN 1; BIOLOGICAL FACTOR; LUCIFERASE; MICRORNA; MICRORNA 603; UNCLASSIFIED DRUG; WNT INHIBITORY FACTOR 1; WNT PROTEIN; CTNNB1 PROTEIN, HUMAN; CTNNBIP1 PROTEIN, HUMAN; MIRN603 MICRORNA, HUMAN; REPRESSOR PROTEIN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; WIF1 PROTEIN, HUMAN;

ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GLIOMA; GLIOMA CELL; GLIOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN ISOLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BRAIN TUMOR; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; GLIOBLASTOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TIME; TUMOR CELL LINE; TUMOR VOLUME; WNT SIGNALING PATHWAY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BETA CATENIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; REPRESSOR PROTEINS; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; WNT SIGNALING PATHWAY;

EID: 84924479415     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.02.003     Document Type: Article

References (43)

1. Wen P.Y., Kesari S. Malignant gliomas in adults. N. Engl. J. Med 2008, 359(5):492-507. Epub 2008/08/02.
2. Niyazi M., Siefert A., Schwarz S.B., Ganswindt U., Kreth F.W., Tonn J.C., et al. Therapeutic options for recurrent malignant glioma. Radiother. Oncol 2011, 98(1):1-14. Epub 2010/12/17.
3. Lai E.C. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat. Genet 2002, 30(4):363-364.
4. Mussnich P., D'Angelo D., Leone V., Croce C.M., Fusco A. The High Mobility Group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression. Mol. Oncol 2013, 7(3):531-542. Epub 2013/02/07.
5. Ayaz L., Gorur A., Yaroglu H.Y., Ozcan C., Tamer L. Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma. J. Cancer Res. Clin. Oncol 2013, 139(9):1499-1506. Epub 2013/07/03.
6. D'Angelo D., Palmieri D., Mussnich P., Roche M., Wierinckx A., Raverot G., et al. Altered MicroRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. J. Clin. Endocr. Metab 2012, 97(7):E1128-E1138.
7. Yu J., Li A., Hong S.M., Hruban R.H., Goggins M. MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin. Cancer Res 2012, 18(4):981-992.
8. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol 2008, 110(1):13-21.
9. Wang F.J., Ding Y., Mao Y.Y., Jing F.Y., Zhang Z.Y., Jiang L.F., et al. Associations between hsa-miR-603 polymorphism, lifestyle-related factors and colorectal cancer risk. Cancer Biomark 2014, 14(4):225-231. Epub 2014/06/18.
10. Kushwaha D., Ramakrishnan V., Ng K., Steed T., Nguyen T., Futalan D., et al. A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas. Oncotarget 2014, 5(12):4026-4039. Epub 2014/07/06.
11. Kaina B., Fritz G., Mitra S., Coquerelle T. Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis 1991, 12(10):1857-1867. Epub 1991/10/01.
12. Sun S., Wang Q., Giang A., Cheng C., Soo C., Wang C.Y., et al. Knockdown of CypA inhibits interleukin-8 (IL-8) and IL-8-mediated proliferation and tumor growth of glioblastoma cells through down-regulated NF-kappaB. J. Neurooncol 2011, 101(1):1-14. Epub 2010/05/11.
13. Tomayko M.M., Reynolds C.P. Determination of subcutaneous tumor size in athymic (Nude) mice. Cancer Chemother. Pharm 1989, 24(3):148-154.
14. Ozawa T., James C.D. Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. J. Vis. Exp 2010, 41. Epub 2010/07/21.
15. Guo P., Hu B., Gu W., Xu L., Wang D., Huang H.J., et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol 2003, 162(4):1083-1093. Epub 2003/03/26.
16. Guo M., Jiang Z., Zhang X., Lu D., Ha A.D., Sun J., et al. miR-656 inhibits glioma tumorigenesis through repression of BMPR1A. Carcinogenesis 2014, 35(8):1698-1706. Epub 2014/02/01.
17. Rheinbay E., Suva M.L., Gillespie S.M., Wakimoto H., Patel A.P., Shahid M., et al. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep 2013, 3(5):1567-1579. Epub 2013/05/28.
18. Li H.P., Zeng X.C., Zhang B., Long J.T., Zhou B., Tan G.S., et al. miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-beta. Carcinogenesis 2013, 34(11):2443-2451. Epub 2013/06/07.
19. Li S.Z., Hu Y.Y., Zhao J., Zhao Y.B., Sun J.D., Yang Y.F., et al. MicroRNA-34a induces apoptosis in the human glioma cell line, A172, through enhanced ROS production and NOX2 expression. Biochem. Biophys. Res. Commun 2014, 444(1):6-12. Epub 2014/01/08.
20. Peng B., Li D., Qin M., Luo D., Zhang X., Zhao H., et al. MicroRNA218 inhibits glioma migration and invasion via inhibiting glioma-associated oncogene homolog 1 expression at N terminus. Tumour Biol 2014, 35(4):3831-3837. Epub 2013/12/21.
21. Auffinger B., Thaci B., Ahmed A., Ulasov I., Lesniak M.S. MicroRNA targeting as a therapeutic strategy against glioma. Curr. Mol. Med 2013, 13(4):535-542.
22. Nikaki A., Piperi C., Papavassiliou A.G. Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy. Expert Opin. Investig. Drugs 2012, 21(10):1475-1488. Epub 2012/07/20.
23. Hsieh J.C., Kodjabachian L., Rebbert M.L., Rattner A., Smallwood P.M., Samos C.H., et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 1999, 398(6726):431-436. Epub 1999/04/14.
24. Yang Z., Wang Y., Fang J., Chen F., Liu J., Wu J., et al. Downregulation of WIF-1 by hypermethylation in astrocytomas. Acta Biochim. Biophys. Sin. (Shanghai) 2010, 42(6):418-425. Epub 2010/06/12.
25. Lambiv W.L., Vassallo I., Delorenzi M., Shay T., Diserens A.C., Misra A., et al. The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro-Oncol 2011, 13(7):736-747. Epub 2011/06/07.
26. Tago K., Nakamura T., Nishita M., Hyodo J., Nagai S., Murata Y., et al. Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein. Genes Dev 2000, 14(14):1741-1749. Epub 2000/07/18.
27. Fransson S., Martinsson T., Ejeskar K. Neuroblastoma tumors with favorable and unfavorable outcomes: significant differences in mRNA expression of genes mapped at 1p36.2. Genes Chromosomes Cancer 2007, 46(1):45-52. Epub 2006/10/18.
28. Persson M., Andren Y., Moskaluk C.A., Frierson H.F., Cooke S.L., Futreal P.A., et al. Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma. Genes Chromosomes Cancer 2012, 51(8):805-817. Epub 2012/04/17.
29. Corbin M., de Reynies A., Rickman D.S., Berrebi D., Boccon-Gibod L., Cohen-Gogo S., et al. WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries?. Genes Chromosomes Cancer 2009, 48(9):816-827. Epub 2009/06/17.
30. Zhuo M., Zhu C., Sun J., Weis W.I., Sun Z. The beta-catenin binding protein ICAT modulates androgen receptor activity. Mol. Endocrinol 2011, 25(10):1677-1688. Epub 2011/09/03.
31. Liu C., Tu Y., Sun X., Jiang J., Jin X., Bo X., et al. Wnt/beta-catenin pathway in human glioma: expression pattern and clinical/prognostic correlations. Clin. Exp. Med 2011, 11(2):105-112. Epub 2010/09/03.
32. Zhang K., Zhang J., Han L., Pu P., Kang C. Wnt/beta-catenin signaling in glioma. J. Neuroimmune Pharmacol 2012, 7(4):740-749. Epub 2012/03/29.
33. Pu P., Zhang Z., Kang C., Jiang R., Jia Z., Wang G., et al. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther 2009, 16(4):351-361. Epub 2008/10/25.
34. Augustin I., Goidts V., Bongers A., Kerr G., Vollert G., Radlwimmer B., et al. The Wnt secretion protein Evi/Gpr177 promotes glioma tumorigenesis. EMBO Mol. Med 2012, 4(1):38-51. Epub 2011/12/08.
35. Reis M., Czupalla C.J., Ziegler N., Devraj K., Zinke J., Seidel S., et al. Endothelial Wnt/beta-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J. Exp. Med 2012, 209(9):1611-1627. Epub 2012/08/22.
36. Chen H.L., Chew L.J., Packer R.J., Gallo V. Modulation of the Wnt/beta-catenin pathway in human oligodendroglioma cells by Sox17 regulates proliferation and differentiation. Cancer Lett 2013, 335(2):361-371. Epub 2013/03/12.
37. Drescher U. A no-Wnt situation: SFRPs as axon guidance molecules. Nat. Neurosci 2005, 8(10):1281-1282.
38. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., et al. Identification of c-MYC as a target of the APC pathway. Science 1998, 281(5382):1509-1512. Epub 1998/09/04.
39. Huang C., Sun Z., Sun Y., Chen X., Zhu X., Fan C., et al. Association of increased ligand cyclophilin A and receptor CD147 with hypoxia, angiogenesis, metastasis and prognosis of tongue squamous cell carcinoma. Histopathology 2012, 60(5):793-803. Epub 2012/02/11.
40. Behrens J., Jerchow B.A., Wurtele M., Grimm J., Asbrand C., Wirtz R., et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 1998, 280(5363):596-599. Epub 1998/05/09.
41. Kanzaki H., Ouchida M., Hanafusa H., Yano M., Suzuki H., Aoe M., et al. Single nucleotide polymorphism of the AXIN2 gene is preferentially associated with human lung cancer risk in a Japanese population. Int. J. Mol. Med 2006, 18(2):279-284. Epub 2006/07/06.
42. Eastman Q., Grosschedl R. Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr. Opin. Cell Biol 1999, 11(2):233-240. Epub 1999/04/21.
43. Musgrove E.A., Caldon C.E., Barraclough J., Stone A., Sutherland R.L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 2011, 11(8):558-572. Epub 2011/07/08.